Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: Results of a phase i study

Keyphrases

• Phase I Study 100%
• Intra-arterial 100%
• Blood-brain Barrier Disruption 100%
• Intra-arterial Chemotherapy 100%
• Oligodendroglial Tumors 100%
• Melphalan 71%
• Tumor 42%
• Maximum Tolerated Dose 42%
• Carboplatin 42%
• Anaplastic Oligodendroglioma 42%
• 1p/19q Deletion 42%
• Etoposide Phosphate 42%
• Dose Escalation 28%
• Thrombocytopenia 28%
• Stable Disease 28%
• Complete Response 28%
• Partial Response 28%
• Anaplastic Oligoastrocytoma 28%
• Temozolomide 14%
• Adverse Events 14%
• Tears 14%
• Progression-free Survival 14%
• 1p Deletion 14%
• Subintimal 14%
• Oligoastrocytoma 14%
• Melphalan Dose 14%
• Temozolomide Refractory 14%
• Chromosome 1p 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Melphalan 100%
• Neoplasm 100%
• Blood-Brain Barrier 100%
• Astrocytoma 50%
• Etoposide Phosphate 50%
• Maximum Tolerated Dose 50%
• Carboplatin 50%
• Oligodendroglioma 50%
• Temozolomide 33%
• Thrombocytopenia 33%
• Diseases 33%
• Adverse Event 16%
• Progression Free Survival 16%

Medicine and Dentistry

• Neoplasm 100%
• Blood Brain Barrier 100%
• Intraarterial Drug Administration 100%
• Melphalan 100%
• Carboplatin 50%
• Oligoastrocytoma 50%
• Oligodendroglioma 50%
• Etoposide Phosphate 50%
• Temozolomide 33%
• Thrombocytopenia 33%
• Diseases 33%
• Adverse Event 16%
• Progression Free Survival 16%
• Chromosome 19q 16%
• Chromosome 1p 16%